Commentary

Increased migratory and homing abilities of neural and mesenchymal stem cell populations by transient cell modifications: Preclinical progress and clinical relevance

Johannes Boltze\textsuperscript{a,}\textsuperscript{*}, Nadine Didwischus\textsuperscript{a}, Shen Li\textsuperscript{b}, Jukka Jolkkonen\textsuperscript{c,d,1}, Akihiko Taguchi\textsuperscript{e,1}

\textsuperscript{a} School of Life Sciences, University of Warwick, Gibbet Hill Road, Coventry CV4 7AL, United Kingdom
\textsuperscript{b} Department of Neurology, Dalian Municipal Central Hospital affiliated with Dalian Medical University, No. 826 Xianan Road, Dalian 116033, China
\textsuperscript{c} A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Neulamiehentie 2, 70150 Kuopio, Finland
\textsuperscript{d} Institute of Clinical Medicine-Neurology, University of Eastern Finland, Yliopistonranta 1 C, 70210 Kuopio, Finland
\textsuperscript{e} Department of Regenerative Medicine Research, Foundation for Biomedical Research and Innovation, Minatojima-Minamimachi 2-2, Kobe 650-0047, Hyogo, Japan

\textbf{A R T I C L E  I N F O}

\textit{Article History:}
Received 2 September 2020
Accepted 9 September 2020
Available online 24 September 2020

Cell-based treatments of central nervous system (CNS) disorders are an emerging paradigm in experimental medicine. Given the anatomical and functional complexity of the mammalian brain, the tempting concept of simply replacing lost or critically affected brain tissue by stem cell transplants appeared difficult to realise. Therapeutic approaches now try to support endogenous regeneration and reorganisation, as well as to prevent secondary damage. This is achieved by paracrine and other so-called bystander effects. Preclinical research revealed a broad spectrum of such mechanisms for two of the most frequently investigated cell populations: mesenchymal stem cells (MSCs) and neural stem cells (NSCs). Although therapeutically relevant systemic effects of MSC and NSC transplantation have been identified, targeted delivery of cells to the brain tissue is considered important to achieve an optimal outcome in CNS disorders.

Clinical trials are subject to a number of logistical and medical requirements. These ensure maximum patient safety and the best possible standard of treatment, but cause significant design differences when compared to preclinical studies using stem cells \cite{1}. For instance, cell populations are predominantly applied intravenously in clinics although more targeted approaches such as stereotaxic transplantation are often more effective in animal experiments. On the other hand, repeated stereotaxic cell administration to place stem cell deposits in the target area is not only logistically challenging, but may increase the risk of secondary brain damage in humans \cite{2}. Alternative approaches such as intra-arterial (carotid) stem cell administration may achieve more targeted cell delivery to the brain while being combined with state-of-the-art recanalization approaches in stroke.

However, intra-carotid administration of relatively large cell populations such as MSCs bears the risk of secondary cerebral vessel occlusion and microlesions \cite{3}. To overcome these limitations, stem cell populations with enhanced migratory abilities are required. These cells would be able to reach the target tissue in greater numbers after systemic or intranasal administration and would egress from blood vessels more swiftly. Two recent publications in this issue of \textit{EBioMedicine} report significant progress in exactly that direction (Fig. 1).

The first manuscript \cite{4} describes the isolation of highly migrating NSC and MSC subpopulations from murine and human cell populations. These subpopulations (sNSC and sMSC, respectively) were able to migrate faster and over longer distances. Detailed transcriptome analyses of these populations revealed an increased expression of podoplanin (PDPN), a factor crucial for regulating stem cell migratory abilities, in the cells. The cells showed superior therapeutic abilities when applied in vitro models of glioblastoma and an animal model of Alzheimer’s disease. Importantly, superior migration abilities were induced by PDPN mRNA transfection allowing for transient modification of the cells. The second manuscript \cite{5} reported that pre-treatment with the cationic molecule polyethylenimine (PEI) increases CCR4 expression on MSCs. Subsequent suppression of adhesion molecule receptors effectively prevented pulmonary filtering, a well-known phenomenon after intravenous delivery of large cell populations such as MSCs, and increased cell homing to the brain. MSC viability and therapeutically essential functions such as immunomodulation and differentiation potential remained unchanged. PEI-modified MSCs were successfully applied in animal models of cerebrovascular disorders, brain excitotoxicity and malignant CNS neoplasm. Those findings are highly relevant to both basic science and clinical medicine for the following reasons.

First, these approaches might be used to augment therapeutically relevant mechanisms of other adult cell populations such as mononuclear cells (MNCs) for which a direct cell–cell interaction in the therapeutically targeted brain tissue is required \cite{6}. The concepts may also help to improve therapeutic application of other cell populations that rely on long-distance targeted migration within the brain such as glial-restricted progenitor cells being used to treat white matter...
damage. Bone marrow-derived MNC therapies for CNS disorders are already in early-stage clinical evaluation and upcoming, efficacy-oriented studies might benefit from these findings.

Third, described cell selection processes and PEI pre-treatment are easily applicable during cell production according to good manufacturing practice and may also inform the development of more specific, treatment-specific potency assays [8]. Moreover, the techniques reported by Danielyan, Schäfer and colleagues achieve similar results than previously described lentiviral approaches [9], but without the necessity for technically challenging or even permanent cell modification. These features may ultimately foster clinical translation of the approach.

Future research shall address some relevant open questions. For instance, it should be carefully analysed whether the increased migratory abilities are sufficient to increase migratory efficacy over the relatively long distances to or within the human brain. Large animal models, which are increasingly used in neurovascular and neurodegenerative research [10], may be helpful in this regard. Large animal brain size and anatomy are closer to the human one. Moreover, the larger volume and migration distances in the human brain present additional challenges for cell tracking approaches. Thus, research on more effective labelling and sensitive detection techniques for swiftly migrating cells is recommended. Finally, long-term investigations should confirm the excellent safety profile of transiently modified MSCs and NSCs.

In summary, the presented work represents a major step in the direction of practical implementation of stem cell therapies for CNS disorders in humans and may inform the development of functionally improved cell products for that purpose.

Declaration of Interests

The authors do not declare any conflict of interests.

Acknowledgements

No external funding was used for this work. We apologize to the numerous colleagues whose relevant work could not be cited due to space restrictions.

References

[1] Cui LL, Golubczyk D, Tolpannen AM, Boltze J, Jolkkonen J. Cell therapy for ischemic stroke: are differences in preclinical and clinical study design responsible for the translational loss of efficacy? Ann Neurol 2019;86(1):5–16 Available from: http://dx.doi.org/. doi: 10.1002/ana.25493.

[2] Boltze J, Arnold A, Walczak P, Jolkkonen J, Cui LL, Wagner DC. The dark side of the force – constraints and complications of cell therapies for stroke. Front Neurol 2015;6:155 Available from: http://dx.doi.org/. doi: 10.3389/fneur.2015.00155.

[3] Cui LL, Kerkela E, Bakreen A, Nitzsche F, Andrzejewska A, Nowakowski A, et al. The cerebral embolism evoked by intra-arterial delivery of allogeneic bone marrow mesenchymal stem cells in rats is related to cell dose and infusion velocity. Stem Cell Res Ther 2015;6(1):11 Available from: http://dx.doi.org/. doi: 10.1186/sct554.

[4] Danielyan L, Schwab M, Siegel G, Brawek B, Garaschuk O, Asavapanumas N, et al. Cell motility and migration as determinants of stem cell efficacy. EBioMedicine 2020. doi: 10.1016/j.ebiom.2020.102989.

[5] Schäfer R, Schwab M, Siegel G, von Ameln-Mayerhofer A, Baadze M, Lourhmari A, et al. Modulating endothelial adhesion and migration impacts stem cell therapies efficacy. EBioMedicine 2020. doi: 10.1016/j.ebiom.2020.102987.

[6] Kikuchi-Taura A, Okinaka Y, Takeuchi Y, Ogawa Y, Maeda M, Kataoka Y, et al. Bone marrow mononuclear cells activate angiogenesis via gap junction-mediated cell-cell interaction. Stroke 2020;51(4):1279–89 Available from: http://dx.doi.org/. doi: 10.1161/STROKEAHA.119.028072.

[7] Savitz SI, Baron JC, Fisher M, STARX Consortium. Stroke treatment academic industry roundtable X: brain cytoprotection therapies in the reperfusion era. Stroke 2019;50(4):1026–31 Available from: http://dx.doi.org/. doi: 10.1161/STROKEAHA.118.029277.

[8] Boltze J, Modo MM, Mays RW, Taguchi A, Jolkkonen J, Savitz SI, et al. Stem cell therapies as an emerging paradigm in stroke 4: advancing and accelerating preclinical research. Stroke 2019;50(9):3299–306 Available from: http://dx.doi.org/. doi: 10.1161/STROKEAHA.119.025436.

[9] Cui LL, Nitzsche F, Pryanishnikov E, Tsybekina M, Tolpannen L, Rytkonen J, et al. Integrin α4 overexpression on rat mesenchymal stem cells enhances transmigration and reduces cerebral embolism after intracarotid injection. Stroke 2017;48(4):2955–900 Available from: http://dx.doi.org/. doi: 10.1161/STROKEAHA.117.018709.

[10] Herrmann AM, Meckel S, Gounis MJ, Kringle I, Motschall E, Mulling C, et al. Large animals in neurointerventional research: a systematic review on models, techniques and their application in endovascular procedures for stroke, aneurysms and vascular malformations. J Cereb Blood Flow Metab 2019;39(3):375–94 Available from: http://dx.doi.org/. doi: 10.1177/0271678X19827446.